חוב לטווח קצר להון Legend Biotech Corporation (LEGN)

The visualized price action of Legend Biotech (LEGN) highlights the impact of laboratory expansion costs and drug sales rates, with the indicator standing at 0.13. The brand enjoys global recognition in oncology due to the quality of its biologics. Legend Biotech (LEGN) generates revenue from the commercialization of myeloma gene therapy through partnership contracts, utilizing advanced CAR receptors.

This ratio determines the share of short-term liabilities within the equity structure, measuring the company's ability to service current loans without compromising financial stability. By analyzing the trend of short-term accounts payable relative to equity, an investor can assess the liquidity of Legend Biotech (LEGN) amid the capital-intensive scaling of CAR-T therapy and regulatory pressure, which is critical for evaluating the issuer's solvency.